Hepatitis C IRES: Translating translation into a therapeutic target

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 3, 2001, Pages 278-287

  Jubin, R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antisense oligonucleotides; Hepatitis C; IRES; Ribozymes; Translation

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BINDING PROTEIN; CELL PROTEIN; FUNGAL RNA; HEPTAZYME; NUCLEOSIDE ANALOG; RIBAVIRIN; RIBOZYME;

ANALYSIS; ARTICLE; CHEMICAL MODIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; HEPATITIS C VIRUS; IN VITRO STUDY; IN VIVO STUDY; RIBOSOME; TECHNIQUE; VIRUS TRANSCRIPTION;

5' UNTRANSLATED REGIONS; BASE SEQUENCE; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS; RIBOSOMES; RNA, CATALYTIC; RNA, VIRAL; THIONUCLEOTIDES;

HEPATITIS C VIRUS;

EID: 0034944233     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
2. Initiation of translation in prokaryotes and eukaryotes
3. Internal initiation of translation in eukaryotes: The picornavirus paradigm and beyond
4. Internal ribosome entry site within hepatitis C virus RNA
5. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism
6. Translation efficiencies of the 5′ untranslated region from representatives of the six major genotypes of hepatitis C virus using a novel bicistronic reporter assay system
7. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
8. The origin of hepatitis C virus genotypes
9. Preclinical and clinical pharmacology of antisense oligonucleotides
10. Sensible use of antisense: How to use oligonucleotides as research tools
11. Unwinding of nucleic acids by HCV NS3 helicase is sensitive to the structure of the duplex
12. Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5′ untranslated of the viral genome
13. Characteristics of nucleotide substitution in the hepatitis C virus genome: Constraints on sequence change in coding regions at both ends of the genome
14. A phylogenetically conserved stem-loop structure at the 5′ border of the internal ribosome entry site of hepatitis C virus is required for cap-indenpendent viral translation
15. Quasispecies in viral persistence and pathogenesis of hepatitis C virus
16. The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold
17. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence
18. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes
19. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity
20. Hepatitis C virus internal ribosome entry site (IRES) stem loop IIId contains a phylogenetically conserved GGG triplet essential for translation and IRES folding
21. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant
22. Internal ribosome entry sites within the RNA genomes of hepatitis C virus and other flaviviruses
23. Mutational analysis of a conserved tetraloop in the 5′ untranslated region of hepatitis C virus identifies a novel RNA element essential for the internal ribosome entry site function
24. A specificity comparision of four antisense types: Morpholino, 2′-O-methyl RNA, DNA and phosphorothioate DNA
25. The structure, function and application of the hammerhead ribozyme
26. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes
27. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes
28. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro
29. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
30. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice
31. Single dose safety and pharmacokinetics of LY466700, a synthetic nuclease-resistant anti-HCV ribozyme, in healthy adult subjects
32. Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines
33. In vivo gene delivery to the liver using novel galactosylated cationic liposomes
34. Functional interactions in internal translation initiation directed by viral and cellular IRES elements
35. Heterogeneous nuclear ribonucleoprotein L interacts with the 3′ border of the internal ribosomal entry site of hepatitis C virus
36. Mechanism of translation initiation on hepatitis C virus RNA
37. The La antigen binds 5′ non-coding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation
38. Post-transcriptional regulation: The dawn of PTB
39. RNA-protein interactions in regulation of picornavirus RNA translation
40. Interaction of polypyrimidine tract-binding protein with the 5′ non-coding region of the hepatitis C virus RNA genome and its functional requirement in internal initiation of translation
41. Transient expression of cellular polypyrimidine-tract binding protein stimulates cap-independent translation directed by both picornaviral and flaviviral internal ribosome entry sites in vivo
42. Demonstration of functional requirement of polypyrimidine tract-binding protein by SELEX RNA during hepatitis C virus internal ribosome entry site-mediated translation initiation
43. Recognition of nascent RNA by the human La antigen: Conserved and divergent features of structure and function
44. Yeast cells are incapable of translating RNAs containing the poliovirus 5′ untranslated region: Evidence for a translational inhibitor
45. A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element
46. Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation
47. Identification of elF2Bγ and elF2γ as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach
48. Pathway and mechanism of protein synthesis
49. Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA
50. Specific interaction of eukaryotic translation initiation factor 3 with the 5′ non-translated regions of hepatitis C virus and classical swine fever virus RNAs
51. An enzymatic footprinting analysis of the interaction of 40S ribosomal subunits with the internal ribosomal entry site of hepatitis C virus
52. Mechanism of ribosome recruitment by hepatitis C IRES RNA
53. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunit
54. A potential RNA drug target in the hepatitis C virus internal ribosomal entry site
55. Structures of two RNA domains essential for hepatitis C virus internal ribosome entry site function
56. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
57. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
58. Efficient initiation of HCV RNA replication in cell culture